Literature DB >> 29491157

Intragastric Administration of Lactobacillus plantarum and 2,2'-Dithiodipyridine-Inactivated Simian Immunodeficiency Virus (SIV) Does Not Protect Indian Rhesus Macaques from Intrarectal SIV Challenge or Reduce Virus Replication after Transmission.

Diane G Carnathan1,2, Joseph J Mackel1,2, Shelby L Sweat1,2, Chiamaka A Enemuo1,2, Etse H Gebru1,2, Pallavi Dhadvai1,2, Sailaja Gangadhara1,2, Sakeenah Hicks1,2, Thomas H Vanderford1,2, Rama R Amara1,2, José Esparza3, Wei Lu4, Jean-Marie Andrieu4, Guido Silvestri5,2.   

Abstract

A major obstacle to development of an effective AIDS vaccine is that along with the intended beneficial responses, the immunization regimen may activate CD4+ T cells that can facilitate acquisition of human immunodeficiency virus (HIV) by serving as target cells for the virus. Lu et al. (W. Lu et al., Cell Rep 2:1736-1746, 2012, https://doi.org/10.1016/j.celrep.2012.11.016) reported that intragastric administration of chemically inactivated simian immunodeficiency virus SIVmac239 and Lactobacillus plantarum (iSIV-L. plantarum) protected 15/16 Chinese-origin rhesus macaques (RMs) from high-dose intrarectal SIVmac239 challenge at 3 months postimmunization. They attributed the observed protection to induction of immune tolerance, mediated by "MHC-Ib/E-restricted CD8+ regulatory T cells that suppressed SIV-harboring CD4+ T cell activation and ex vivo SIV replication in 15/16 animals without inducing SIV-specific antibodies or cytotoxic T." J.-M. Andrieu et al. (Front Immunol 5:297, 2014, https://doi.org/10.3389/fimmu.2014.00297) subsequently reported protection from infection in 23/24 RMs immunized intragastrically or intravaginally with iSIV and Mycobacterium bovis BCG, L. plantarum, or Lactobacillus rhamnosus, which they ascribed to the same tolerogenic mechanism. Using vaccine materials obtained from our coauthors, we conducted an immunization and challenge experiment with 54 Indian RMs and included control groups receiving iSIV only or L. plantarum only as well as unvaccinated animals. Intrarectal challenge with SIVmac239 resulted in rapid infection in all groups of vaccinated RMs as well as unvaccinated controls. iSIV-L. plantarum-vaccinated animals that became SIV infected showed viral loads similar to those observed in animals receiving iSIV only or L. plantarum only or in unvaccinated controls. The protection from SIV transmission conferred by intragastric iSIV-L. plantarum administration reported previously for Chinese-origin RMs was not observed when the same experiment was conducted in a larger cohort of Indian-origin animals.IMPORTANCE Despite an increased understanding of immune responses against HIV, a safe and effective AIDS vaccine is not yet available. One obstacle is that immunization may activate CD4+ T cells that may act as target cells for acquisition of HIV. An alternative strategy may involve induction of a tolerance-inducing response that limits the availability of activated CD4+ T cells, thus limiting the ability of virus to establish infection. In this regard, exciting results were obtained for Chinese-origin rhesus macaques by using a "tolerogenic" vaccine, consisting of intragastric administration of Lactobacillus plantarum and 2,2'-dithiodipyridine-inactivated SIV, which showed highly significant protection from virus transmission. In the present study, we administered iSIV-L. plantarum to Indian-origin rhesus macaques and failed to observe any protective effect on virus acquisition in this experimental setting. This work is important because it contributes to the overall assessment of the clinical potential of a new candidate AIDS vaccine platform based on iSIV-L. plantarum.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  SIV vaccine; oral vaccines

Mesh:

Substances:

Year:  2018        PMID: 29491157      PMCID: PMC5923080          DOI: 10.1128/JVI.02030-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins.

Authors:  Elena Chertova; Bruce J Crise; David R Morcock; Julian W Bess; Louis E Henderson; Jeffrey D Lifson
Journal:  Curr Mol Med       Date:  2003-05       Impact factor: 2.222

2.  CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Authors:  Suefen Kwa; Lilin Lai; Sailaja Gangadhara; Mariam Siddiqui; Vinod B Pillai; Celia Labranche; Tianwei Yu; Bernard Moss; David C Montefiori; Harriet L Robinson; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

3.  Peptide-binding motifs associated with MHC molecules common in Chinese rhesus macaques are analogous to those of human HLA supertypes and include HLA-B27-like alleles.

Authors:  Bianca R Mothé; Scott Southwood; John Sidney; A Michelle English; Amanda Wriston; Ilka Hoof; Jeffrey Shabanowitz; Donald F Hunt; Alessandro Sette
Journal:  Immunogenetics       Date:  2013-02-17       Impact factor: 2.846

4.  SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.

Authors:  Binhua Ling; Ronald S Veazey; Amara Luckay; Cecilia Penedo; Keyu Xu; Jeffrey D Lifson; Preston A Marx
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

5.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Authors:  Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

Review 6.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

Review 7.  HIV-Host Interactions: Implications for Vaccine Design.

Authors:  Barton F Haynes; George M Shaw; Bette Korber; Garnett Kelsoe; Joseph Sodroski; Beatrice H Hahn; Persephone Borrow; Andrew J McMichael
Journal:  Cell Host Microbe       Date:  2016-02-25       Impact factor: 21.023

Review 8.  SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans.

Authors:  Yu Zhou; Rong Bao; Nancy L Haigwood; Yuri Persidsky; Wen-zhe Ho
Journal:  Retrovirology       Date:  2013-08-15       Impact factor: 4.602

9.  Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.

Authors:  Jean-Marie Andrieu; Song Chen; Chunhui Lai; Weizhong Guo; Wei Lu
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

10.  Suppression of HIV Replication by CD8(+) Regulatory T-Cells in Elite Controllers.

Authors:  Wei Lu; Song Chen; Chunhui Lai; Mingyue Lai; Hua Fang; Hong Dao; Jun Kang; Jianhua Fan; Weizhong Guo; Linchun Fu; Jean-Marie Andrieu
Journal:  Front Immunol       Date:  2016-04-18       Impact factor: 7.561

View more
  1 in total

Review 1.  A 30-year journey of trial and error towards a tolerogenic AIDS vaccine.

Authors:  Jean-Marie Andrieu; Wei Lu
Journal:  Arch Virol       Date:  2018-07-24       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.